SINOPHARM submit the proposal of booster shot of COVID-19 vaccine

News

SINOPHARM submit the proposal of booster shot of COVID-19 vaccine, and is currently improving the construction of the mRNA platform and the layout of large-scale production workshops.

SINOPHARM submit the proposal of booster shot of COVID-19 vaccine.

China Daily, September 5, A reporter from China Daily learned exclusively that SINOPHARM China Biotechnology Co., Ltd. has submitted a third dose proposal for the COVID-19 pneumonia inactivated vaccine to relevant authorities.

In an exclusive interview with a reporter from China Daily at the China International Trade in Services Fair in 2021, Chen Kun, secretary of the China Biodisciplinary Commission of SINOPHARM Group, said that existing experimental data show that the company’s inactivated vaccine for COVID-19 pneumonia is still effective against existing major COVID-19 virus variants. .

He told reporters that SINOPHARM China’s bio-related experiments also showed that six months after the completion of the company’s two-injection vaccine immunization program, the booster vaccination can increase the antibody level of subjects by up to 5-10 times, which can be greatly improved. Improve immunity. The plan suggests that for special groups such as the elderly and window service industry practitioners, another booster shot can be given within 6 months to 1 year after the completion of the two-dose vaccination program.

SINOPHARM submit the proposal of booster shot of COVID-19 vaccine.
SINOPHARM Group China Bio is located in the exhibition area of the Shougang Garden Health Service Exhibition Hall of the 2021 Service Trade Fair

At this service trade fair, SINOPHARM Group China Biotech presented the latest scientific and technological achievements in the fight against the COVID-19 epidemic at the Shougang Garden Health Service Exhibition Hall, including 3 diagnostic reagents in the “diagnosable” field and 2 in the “curable” field Specific drugs (specific immunoglobulins, monoclonal antibodies) and 4 COVID-19 vaccines developed on 3 technical routes in the “preventable” field.

It is reported that SINOPHARM China Biosciences independently develops 4 vaccines on 3 technical routes (inactivation, genetic recombination, and mRNA). The two new inactivated vaccines of the Beijing Institute of Biological Products and Wuhan Institute of Biological Products have been approved for marketing. At this service and trade fair, China Biologics carried two upgraded versions of the COVID-19 inactivated vaccines, and the second-generation COVID-19 inactivated vaccines that can effectively neutralize the mutant strains were unveiled.

In addition to inactivated vaccines, China Biotech will also display recombinant protein COVID-19 vaccines and mRNA variant COVID-19 vaccines. Recombinant protein COVID-19 vaccine is the world’s leading broad-spectrum recombinant COVID-19 vaccine tailored to virus mutations. From the perspective of clinical trials, this vaccine can effectively fight against mutant strains such as delta. Its mRNA variant strain COVID-19 vaccine has independent intellectual property rights and characteristic advantages, and is currently improving the construction of the mRNA platform and the layout of large-scale production workshops.

(source:internet, reference only)

Disclaimer of medicaltrend.org